David Lorente

David Lorente

Auto-generated profile, based on publicly available information

David Lorente

Servicio de Urología, Hospital de la Vall d'Hebrón, Universidad Autónoma de Barcelona, Barcelona, España

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in Journal of Endourology
Verified
Journal Article
Closed access
JPJosé Placer
José Placer
CSCarlos Salvador
Carlos Salvador
JPJacques Planas
Jacques Planas
ETEnrique Trilla
Enrique Trilla
DLDavid Lorente
David Lorente
JMJuan Morote
Juan Morote
Objective: To evaluate the effects of holmium laser enucleation of the prostate (HoLEP) on sexual function. Methods: A retrospective analysis of 202 sexually active patients who underwent HoLEP was performed. Patients were assessed at baseline and 3 and 12 months post-HoLEP. Evaluations included uroflowmetry and symptom questionnaires (five-item version of the International Index of Erectile Function [IIEF-5], ICIQ-male sexual matters associated with LUTS [ICIQ-MLUTSsex], American Urological Association symptom score [AUA-SS], and single-question quality of life [QoL] score). Nonparametric, Fisher's exact, and chi-squared tests were used to assess changes from baseline and to identify risk factors, if any, associated with deterioration of sexual function after surgery. Results: No significant differences were found between the preoperative and postoperative scores on the questionnaires that evaluated erection quality. However, 6.9% and 12.4% of the patients reported an increase or a reduction, respectively, of greater than five points in total IIEF-5 score. The reduction in IIEF-5 score was statistically significant only in the subgroup of patients without preoperative erectile dysfunction (ED). No preoperative characteristics and no parameters related to the surgery or postoperative outcome were significantly associated with the impairment of erection quality after surgery. In fact, neither capsular perforation nor the total laser energy used during the procedure affected erections. Loss of antegrade ejaculation was found in 70.3% of patients, while 21% reported a reduction in semen quantity. However, concern regarding ED or ejaculatory dysfunctions decreased with surgery. Conclusions: Although erectile function was not altered in the vast majority of patients after HoLEP, patients without preoperative ED displayed a relatively small, but still significant, negative effect on erections. The overwhelming majority of patients suffered from retrograde ejaculation after surgery.

13 August 2010 in BJU International
Verified
Journal Article
Closed access
PDF file
MLMiguel A. Lopez‐Costea
Miguel A. Lopez‐Costea
LFLluís Fumadó
Lluís Fumadó
DLDavid Lorente
David Lorente
LRLuis Riera
Luis Riera
EMEladio Franco Miranda
Eladio Franco Miranda

14 September 2016 in Scandinavian Journal of Urology
Verified
Journal Article
Closed access
JPJacques Planas
Jacques Planas
ACAna Celma
Ana Celma
JPJosé Placer
José Placer
MCMercè Cuadras
Mercè Cuadras
LRLucas Regis
Lucas Regis
JMJuan Morote
Juan Morote
Objective: The aim of this study was to evaluate hormonal recovery after cessation of androgen deprivation therapy (ADT) in a group of elderly prostate cancer patients. Materials and methods: Forty patients with locally advanced or metastatic prostate cancer, with a mean age of 71.5 years [95% confidence interval (CI) 69.1–73.9], were treated with ADT for a mean duration of 74.6 months (95% CI 59.7–89.5 months). Mean follow-up time after ADT cessation was 36.5 months (95% CI 30.6–42.3 months). Serum testosterone and luteinizing hormone (LH) were determined at 6 month intervals after ADT cessation. Results: After 18 months of follow-up, all patients had recovered normal LH levels, while 38% of patients still presented castration levels of testosterone (< 50 ng/dl). A multivariate analysis was performed to find factors related to testosterone recovery (testosterone >50 ng/dl). Neither age at start of ADT nor clinical stage reached statistical significance. Only time under ADT was correlated with testosterone recovery (p = .031). Kaplan–Meier curves were obtained. Mean time for testosterone recovery was 14.5 months (95% CI 6.5–22.6 months) in patients treated with ADT for less than 60 months compared to 29.3 months (95% CI 19.6–39.1 months) in patients treated with ADT for more than 60 months (log-rank p = .029). Conclusions: Age did not correlate with testosterone recovery in a group of elderly prostate cancer patients in whom ADT was stopped. Testosterone recovery after ADT cessation was significantly correlated with time under ADT treatment. Significant implications related to economic aspects of the dosage schedule may be considered.

1 April 2019 in Actas Urológicas Españolas
Verified
Journal Article
Closed access
DLD. Lorente
D. Lorente
EHEnrique Trilla Herrera
Enrique Trilla Herrera
AMA. Meseguer
A. Meseguer
JAJazmine Arevalo
Jazmine Arevalo
SNS. Nemours
S. Nemours
JMJ. Morote
J. Morote

1 January 2019 in Central European Journal of Urology
Verified
Journal Article
Open access
CKCristian Konstantinidis
Cristian Konstantinidis
ETEnrique Trilla
Enrique Trilla
XSXavier Serres-Créixams
Xavier Serres-Créixams
CMCarolina Montealegre
Carolina Montealegre
DLDavid Lorente
David Lorente
JMJuan Morote
Juan Morote
Introduction An association between the R.E.N.A.L. nephrometry score (RNS) and clinical outcomes in patients with a small renal mass (SRM) has been proposed. We analyzed clinical outcomes according to the RNS in patients with a SRM treated with percutaneous contrast enhanced ultrasound (CEUS) radiofrequency ablation (RFA). Material and methods Patients with a SRM, who underwent RFA between January 2005 and March 2015, were retrospectively identified. The association between RNS and clinical outcomes was evaluated using parametric and non-parametric analysis. Results We analyzed 163 SRMs in 149 consecutive patients. The mean age was 71.7 years. Mean followup time was 33.3 months +/- 20.6 (2-102). The mean RNS was 5.6 +/- 1.52 (4-11). A total of 121 (74.2%) cases were of low complexity and 42 (25.8%) were medium complexity. We identified 11 cases of tumor persistence (6.7%). The mean RNS was 5.58 in the cases with no persistence and 5.73 in the cases with persistence (p = 0.788). We identified 15 (9.2%) cases of recurrence. The mean RNS was 5.57 +/- 0.1 (4-11) in the cases without recurrence and 5.73 +/- 0.4 (4-9) in recurrence cases (p = 0.804). Of the 76 biopsy proven RCC cases, 8 (10.5%) cases of recurrence were observed, 5 in the low complexity group and 3 in the medium complexity group (p = 0.690). A total of 9 (5.5%) cases of complications were observed, with 5 (4.3%) in the low complexity group and 4 cases in the medium complexity group (p = 0.23). The mean length of stay was 1.5 days with a significant difference between low and medium complexity groups (1.3 vs. 2.1 days, p = 0.02). The mean difference between preoperative eGFR and estimated eGFRat 12 months was-3.08 mL/min +/- 13.3 (-49.4-34.1) and was significant (p = 0.008).However, this variation did not show significant differences between the low and medium complexity groups (p = 0.936). Allcause mortality was 11.7%, 14 cases (11.6%) in the low complexity group and 5 (11.9%) in the medium complexity group (p = 1.0). No cases of renal cell carcinoma (RCC) specific mortality were identified. Conclusions The RNS was not associated with tumor persistence, recurrence, cancer specific mortality, complications or renal function 12 months after the first treatment, showing significant difference only in length of hospital stay between low and medium complexity groups.

1 April 2019 in Actas Urológicas Españolas
Verified
Journal Article
Closed access
LRLucas Regis
Lucas Regis
ASA. Salazar
A. Salazar
MCM. Cuadras
M. Cuadras
EME. Miret
E. Miret
SRS. Roche
S. Roche
JMJ. Morote
J. Morote